Heba A. Hassan

755 total citations
31 papers, 595 citations indexed

About

Heba A. Hassan is a scholar working on Organic Chemistry, Molecular Biology and Oncology. According to data from OpenAlex, Heba A. Hassan has authored 31 papers receiving a total of 595 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Organic Chemistry, 12 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Heba A. Hassan's work include Synthesis and biological activity (20 papers), Synthesis and Characterization of Heterocyclic Compounds (7 papers) and Quinazolinone synthesis and applications (6 papers). Heba A. Hassan is often cited by papers focused on Synthesis and biological activity (20 papers), Synthesis and Characterization of Heterocyclic Compounds (7 papers) and Quinazolinone synthesis and applications (6 papers). Heba A. Hassan collaborates with scholars based in Egypt, Japan and Saudi Arabia. Heba A. Hassan's co-authors include Mohamed Abdel‐Aziz, Dalia Abdelhamid, Gamal El‐Din A. Abuo‐Rahma, Bahaa G. M. Youssif, Samar H. Abbas, Masami Otsuka, Mikako Fujita, Tamer S. Kaoud, Ahmed M. Gouda and Kevin N. Dalby and has published in prestigious journals such as Molecules, European Journal of Medicinal Chemistry and Bioorganic & Medicinal Chemistry.

In The Last Decade

Heba A. Hassan

31 papers receiving 587 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Heba A. Hassan Egypt 14 387 261 94 50 43 31 595
Samir Mehndiratta Taiwan 17 384 1.0× 363 1.4× 110 1.2× 37 0.7× 19 0.4× 28 744
Gurubasavaraja Swamy Purawarga Matada India 16 332 0.9× 182 0.7× 114 1.2× 73 1.5× 18 0.4× 53 551
Changkun Hu United States 10 414 1.1× 316 1.2× 82 0.9× 29 0.6× 19 0.4× 26 691
Sultan Nacak Baytaş Türkiye 17 477 1.2× 267 1.0× 51 0.5× 30 0.6× 28 0.7× 34 694
Ola I. A. Salem Egypt 14 418 1.1× 217 0.8× 76 0.8× 58 1.2× 17 0.4× 26 586
Manolis A. Fousteris Greece 16 341 0.9× 273 1.0× 97 1.0× 39 0.8× 21 0.5× 40 590
Taijin Wang China 10 201 0.5× 264 1.0× 124 1.3× 45 0.9× 26 0.6× 25 447
Ghada H. Al-Ansary Egypt 15 513 1.3× 369 1.4× 109 1.2× 45 0.9× 77 1.8× 21 699
Youlu Pan China 14 219 0.6× 262 1.0× 122 1.3× 76 1.5× 28 0.7× 38 609
Rajesh Kakadiya Taiwan 16 506 1.3× 335 1.3× 86 0.9× 26 0.5× 16 0.4× 35 695

Countries citing papers authored by Heba A. Hassan

Since Specialization
Citations

This map shows the geographic impact of Heba A. Hassan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heba A. Hassan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heba A. Hassan more than expected).

Fields of papers citing papers by Heba A. Hassan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heba A. Hassan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heba A. Hassan. The network helps show where Heba A. Hassan may publish in the future.

Co-authorship network of co-authors of Heba A. Hassan

This figure shows the co-authorship network connecting the top 25 collaborators of Heba A. Hassan. A scholar is included among the top collaborators of Heba A. Hassan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heba A. Hassan. Heba A. Hassan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mohamed, Mamdouh F. A., et al.. (2025). A review of recent advances in anticancer activity and SAR of pyrazole derivatives. Archiv der Pharmazie. 358(3). e2400470–e2400470. 7 indexed citations
2.
Ali, Taha F. S., et al.. (2023). New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization. Molecular Diversity. 28(2). 563–580. 20 indexed citations
3.
Al-Wahaibi, Lamya H., et al.. (2023). Quinazolin-4-one/3-cyanopyridin-2-one Hybrids as Dual Inhibitors of EGFR and BRAFV600E: Design, Synthesis, and Antiproliferative Activity. Pharmaceuticals. 16(11). 1522–1522. 5 indexed citations
4.
Hassan, Heba A., et al.. (2023). The main biotargets of indole or 2-oxoindole-based hybrids acting as promising antiproliferative agents. 6(4). 174–183. 3 indexed citations
5.
6.
Ali, Taha F. S., et al.. (2023). Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia. BMC Chemistry. 17(1). 73–73. 13 indexed citations
7.
Hassan, Heba A., Mikako Fujita, Masami Otsuka, et al.. (2023). Design and synthesis of new quinoline-ester/-amide derivatives as potent antiproliferative agent targeting EGFR and BRAFV600E kinases. Journal of Molecular Structure. 1297. 136953–136953. 11 indexed citations
8.
Mustafa, Muhamad, et al.. (2023). Hydantoin derivatives: A review on their anticancer activities. 0(0). 0–0. 3 indexed citations
9.
Hassan, Abdelfattah, Mohamed Badr, Dalia Abdelhamid, et al.. (2022). Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold. Bioorganic Chemistry. 120. 105631–105631. 17 indexed citations
10.
Hassan, Abdelfattah, Mohamed Badr, Heba A. Hassan, Dalia Abdelhamid, & Gamal El‐Din A. Abuo‐Rahma. (2021). Novel 4-(piperazin-1-yl)quinolin-2(1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition. Bioorganic & Medicinal Chemistry. 40. 116168–116168. 32 indexed citations
11.
Hassan, Heba A., Dalia Abdelhamid, Ahmed M. Gouda, et al.. (2021). New quinoline/1,2,4-triazole hybrids as dual inhibitors of COX-2/5-LOX and inflammatory cytokines: Design, synthesis, and docking study. Journal of Molecular Structure. 1244. 130948–130948. 25 indexed citations
12.
Abuo‐Rahma, Gamal El‐Din A., Abdelfattah Hassan, Heba A. Hassan, & Dalia Abdelhamid. (2021). Synthetic Approaches toward Certain Structurally Related Antimicrobial Thiazole Derivatives (2010-2020). Heterocycles. 102(9). 1675–1675. 5 indexed citations
13.
Hassan, Heba A., et al.. (2020). STAT3 transcription factor as target for anti-cancer therapy. Pharmacological Reports. 72(5). 1101–1124. 48 indexed citations
14.
Hassan, Heba A., Dalia Abdelhamid, Ahmed M. Gouda, et al.. (2020). Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAFV600E kinases. Bioorganic Chemistry. 106. 104510–104510. 93 indexed citations
15.
Abbas, Samar H., Amer Ali Abd El‐Hafeez, Mai E. Shoman, Monica M. Montano, & Heba A. Hassan. (2018). New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity. Bioorganic Chemistry. 82. 360–377. 52 indexed citations
16.
17.
Hassan, Heba A., et al.. (2017). Cytotoxic Drugs Safety Guidelines: Its Effect on Awareness and Safe Handling Practices of Oncology Nurses. IOSR Journal of Nursing and health Science. 6(3). 22–33. 10 indexed citations
18.
El-Baky, Rehab Mahmoud Abd, et al.. (2016). Fluoroquinolones as Urease Inhibitors: Anti-Proteus mirabilis Activity and Molecular Docking Studies. American journal of microbiological research. 4(3). 81–84. 14 indexed citations
19.
Abdel‐Aziz, Mohamed, Gamal El‐Din A. Abuo‐Rahma, Heba A. Hassan, & Hassan H. Farag. (2009). N‐Malonyl‐1,2‐dihydroisoquinoline as a Novel Carrier for Specific Delivery of Drugs to the Brain. Archiv der Pharmazie. 343(1). 54–60. 7 indexed citations
20.
Hassan, Heba A., Mohamed Abdel‐Aziz, Gamal El‐Din A. Abuo‐Rahma, & Hassan H. Farag. (2008). 1-Malonyl-1,4-dihydropyridine as a novel carrier for specific delivery of drugs to the brain. Bioorganic & Medicinal Chemistry. 17(4). 1681–1692. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samir Mehndiratta Breakdown of academic impact, for papers by Gurubasavaraja Swamy Purawarga Matada Breakdown of academic impact, for papers by Changkun Hu Breakdown of academic impact, for papers by Sultan Nacak Baytaş Breakdown of academic impact, for papers by Ola I. A. Salem Breakdown of academic impact, for papers by Manolis A. Fousteris Breakdown of academic impact, for papers by Taijin Wang Breakdown of academic impact, for papers by Ghada H. Al-Ansary Breakdown of academic impact, for papers by Youlu Pan Breakdown of academic impact, for papers by Rajesh Kakadiya
Rankless by CCL
2026